{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:39:18Z","timestamp":1770680358680,"version":"3.49.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40272-022-00526-x","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T03:21:51Z","timestamp":1659064911000},"page":"433-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-0917","authenticated-orcid":false,"given":"David P.","family":"Douglass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7916-6382","authenticated-orcid":false,"given":"Fariba","family":"Navid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-3963","authenticated-orcid":false,"given":"Aaron R.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"526_CR1","unstructured":"Board WC of TE. WHO classification of tumours\u2014soft tissue and bone tumours. 5th ed. 2020."},{"key":"526_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11912-021-01026-w","volume":"23","author":"R Ratan","year":"2021","unstructured":"Ratan R, Roland CL, Bishop AJ. Desmoid fibromatosis: management in an era of increasing options. Curr Oncol Rep. 2021;23:41.","journal-title":"Curr Oncol Rep"},{"key":"526_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/CCO.0000000000000743","volume":"33","author":"N Penel","year":"2021","unstructured":"Penel N, Kasper B, Graaf WTAD. Desmoid-type fibromatosis: toward a holistic management. Curr Opin Oncol. 2021;33:309\u201314.","journal-title":"Curr Opin Oncol."},{"key":"526_CR4","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1245\/s10434-020-09395-5","volume":"28","author":"M Fiore","year":"2021","unstructured":"Fiore M, Crago A, Gladdy R, Kasper B. The landmark series: desmoid. Ann Surg Oncol. 2021;28:1682\u20139.","journal-title":"Ann Surg Oncol"},{"key":"526_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1586\/14737140.2015.1096203","volume":"15","author":"M Al-Jazrawe","year":"2015","unstructured":"Al-Jazrawe M, Au M, Alman B. Optimal therapy for desmoid tumors: current options and challenges for the future. Expert Rev Anticanc. 2015;15:1443\u201358.","journal-title":"Expert Rev Anticanc"},{"key":"526_CR6","first-page":"43","volume":"21","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Shi J, Yang T, Liu T, Zhang K. Management of aggressive fibromatosis. Oncol Lett. 2021;21:43.","journal-title":"Oncol Lett"},{"key":"526_CR7","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1245\/s10434-015-4632-y","volume":"22","author":"DLM van Broekhoven","year":"2015","unstructured":"van Broekhoven DLM, Gr\u00fcnhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22:2817\u201323.","journal-title":"Ann Surg Oncol"},{"key":"526_CR8","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1200\/JCO.2010.33.5489","volume":"29","author":"S Salas","year":"2011","unstructured":"Salas S, Dufresne A, Bui B, Blay J-Y, Terrier P, Ranchere-Vince D, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29:3553\u20138.","journal-title":"J Clin Oncol"},{"key":"526_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ajcp\/77.6.665","volume":"77","author":"JJ Reitamo","year":"1982","unstructured":"Reitamo JJ, H\u00e4yry P, Nykyri E, Saxen E. The desmoid tumor. I.: Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77:665\u201373.","journal-title":"Am J Clin Pathol."},{"key":"526_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cncr.21553","volume":"106","author":"AT Deyrup","year":"2006","unstructured":"Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-\u03b2 expression in extraabdominal fibromatoses. Cancer. 2006;106:208\u201313.","journal-title":"Cancer"},{"key":"526_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/0002-9610(86)90076-0","volume":"151","author":"JJ Reitamo","year":"1986","unstructured":"Reitamo JJ, Schelnin TM, H\u00e4yry P. The desmoid syndrome: new aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg. 1986;151:230\u20137.","journal-title":"Am J Surg"},{"key":"526_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10689-016-9905-5","volume":"15","author":"S Septer","year":"2016","unstructured":"Septer S, Lawson CE, Anant S, Attard T. Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate. Fam Cancer. 2016;15:477\u201385.","journal-title":"Fam Cancer"},{"key":"526_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1097\/DCR.0b013e318227e4e8","volume":"54","author":"MH Nieuwenhuis","year":"2011","unstructured":"Nieuwenhuis MH, Lefevre JH, B\u00fclow S, J\u00e4rvinen H, Bertario L, Kern\u00e9is S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54:1229\u201334.","journal-title":"Dis Colon Rectum"},{"key":"526_CR14","doi-asserted-by":"crossref","unstructured":"Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22.","DOI":"10.1186\/1750-1172-4-22"},{"key":"526_CR15","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/2159-8290.CD-21-0190","volume":"11","author":"MJ Parsons","year":"2021","unstructured":"Parsons MJ, Tammela T, Dow LE. WNT as a driver and dependency in cancer. Cancer Discov. 2021;11:2413\u201329.","journal-title":"Cancer Discov"},{"key":"526_CR16","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/jnci\/djz026","volume":"111","author":"M Nomura","year":"2019","unstructured":"Nomura M, Rainusso N, Lee Y-C, Dawson B, Coarfa C, Han R, et al. Tegavivint and the \u03b2-catenin\/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma. Jnci J National Cancer Inst. 2019;111:1216.","journal-title":"Jnci J National Cancer Inst."},{"key":"526_CR17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/leu.2014.340","volume":"29","author":"W Fiskus","year":"2015","unstructured":"Fiskus W, Sharma S, Saha S, Shah B, Devaraj SGT, Sun B, et al. Pre-clinical efficacy of combined therapy with novel \u03b2-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015;29:1267\u201378.","journal-title":"Leukemia"},{"key":"526_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/gcc.22272","volume":"54","author":"AM Crago","year":"2015","unstructured":"Crago AM, Chmielecki J, Rosenberg M, O\u2019Connor R, Byrne C, Wilder FG, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54:606\u201315.","journal-title":"Genes Chromosomes Cancer"},{"key":"526_CR19","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1242\/jcs.013771","volume":"120","author":"W Xu","year":"2007","unstructured":"Xu W, Kimelman D. Mechanistic insights from structural studies of \u03b2-catenin and its binding partners. J Cell Sci. 2007;120:3337\u201344.","journal-title":"J Cell Sci"},{"key":"526_CR20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2353\/ajpath.2008.080475","volume":"173","author":"AJF Lazar","year":"2008","unstructured":"Lazar AJF, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the \u03b2-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathology. 2008;173:1518\u201327.","journal-title":"Am J Pathology."},{"key":"526_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40591-015-0038-2","volume":"3","author":"MV Enzo","year":"2015","unstructured":"Enzo MV, Rastrelli M, Rossi CR, Hladnik U, Segat D. The Wnt\/\u03b2-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. Mol Cell Ther. 2015;3:1.","journal-title":"Mol Cell Ther."},{"key":"526_CR22","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cam4.669","volume":"5","author":"C Meazza","year":"2016","unstructured":"Meazza C, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, et al. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. Cancer Med-US. 2016;5:1204\u201313.","journal-title":"Cancer Med-US."},{"key":"526_CR23","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1038\/s41598-020-60237-6","volume":"10","author":"M Trautmann","year":"2020","unstructured":"Trautmann M, Rehk\u00e4mper J, Gevensleben H, Becker J, Wardelmann E, Hartmann W, et al. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis\u2014a systematic analysis of 204 cases. Sci Rep-UK. 2020;10:3368.","journal-title":"Sci Rep-UK."},{"key":"526_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/archsurg.1989.01410020061010","volume":"124","author":"MC Posner","year":"1989","unstructured":"Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor: not a benign disease. Arch Surg-Chicago. 1989;124:191\u20136.","journal-title":"Arch Surg-Chicago."},{"key":"526_CR25","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cgh.2007.06.010","volume":"5","author":"C Durno","year":"2007","unstructured":"Durno C, Monga N, Bapat B, Berk T, Cohen Z, Gallinger S. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol H. 2007;5:1190\u20134.","journal-title":"Clin Gastroenterol H"},{"key":"526_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/cancers4010295","volume":"4","author":"JN Honeyman","year":"2012","unstructured":"Honeyman JN, Quaglia MPL. Desmoid tumors in the pediatric population. Cancers. 2012;4:295\u2013306.","journal-title":"Cancers"},{"key":"526_CR27","doi-asserted-by":"crossref","unstructured":"Oudot C, Orbach D, Minard-Colin V, Michon J, Mary P, Glorion C, et al. Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature. Sarcoma. 2012;2012:1\u20139.","DOI":"10.1155\/2012\/475202"},{"key":"526_CR28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/cncr.24679","volume":"116","author":"C Meazza","year":"2010","unstructured":"Meazza C, Bisogno G, Gronchi A, Fiore M, Cecchetto G, Alaggio R, et al. Aggressive fibromatosis in children and adolescents. Cancer. 2010;116:233\u201340.","journal-title":"Cancer"},{"key":"526_CR29","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1200\/JCO.1995.13.11.2813","volume":"13","author":"LB Faulkner","year":"1995","unstructured":"Faulkner LB, Hajdu SI, Kher U, Quaglia ML, Exelby PR, Heller G, et al. Pediatric desmoid tumor: retrospective analysis of 63 cases. J Clin Oncol. 1995;13:2813\u20138.","journal-title":"J Clin Oncol"},{"key":"526_CR30","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1245\/s10434-013-3090-7","volume":"20","author":"MA Soto-Miranda","year":"2013","unstructured":"Soto-Miranda MA, Sandoval JA, Rao B, Neel M, Krasin M, Spunt S, et al. Surgical treatment of pediatric desmoid tumors. a 12-year, single-center experience. Ann Surg Oncol. 2013;20:3384\u201390.","journal-title":"Ann Surg Oncol."},{"key":"526_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ejso.2007.06.006","volume":"34","author":"S Bonvalot","year":"2008","unstructured":"Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol Ejso. 2008;34:462\u20138.","journal-title":"Eur J Surg Oncol Ejso."},{"key":"526_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2352-4642(17)30045-7","volume":"1","author":"D Orbach","year":"2017","unstructured":"Orbach D, Brennan B, Bisogno G, Noesel MV, Minard-Colin V, Daragjati J, et al. The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. Lancet Child Adolesc Heal. 2017;1:284\u201392.","journal-title":"Lancet Child Adolesc Heal."},{"key":"526_CR33","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/00000658-199906000-00014","volume":"229","author":"JJ Lewis","year":"1999","unstructured":"Lewis JJ, Boland PJ, Leung DHY, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg. 1999;229:866.","journal-title":"Ann Surg"},{"key":"526_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00003086-200006000-00025","volume":"375","author":"G Pignatti","year":"2000","unstructured":"Pignatti G, Barbanti-Br\u00f2dano G, Ferrari D, Gherlinzoni F, Bertoni F, Bacchini P, et al. Extraabdominal desmoid tumor. Clin Orthop Relat R. 2000;375:207\u201313.","journal-title":"Clin Orthop Relat R"},{"key":"526_CR35","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/bjs.5425","volume":"93","author":"AR Latchford","year":"2006","unstructured":"Latchford AR, Sturt NJH, Neale K, Rogers PA, Phillips RKS. A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Brit J Surg. 2006;93:1258\u201364.","journal-title":"Brit J Surg."},{"key":"526_CR36","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1245\/s10434-009-0586-2","volume":"16","author":"M Fiore","year":"2009","unstructured":"Fiore M, Rimareix F, Mariani L, Domont J, Collini P, P\u00e9choux CL, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587\u201393.","journal-title":"Ann Surg Oncol"},{"key":"526_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejca.2014.11.019","volume":"51","author":"C Colombo","year":"2015","unstructured":"Colombo C, Miceli R, P\u00e9choux CL, Palassini E, Honor\u00e9 C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015;51:186\u201392.","journal-title":"Eur J Cancer"},{"key":"526_CR38","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1245\/s10434-013-3197-x","volume":"20","author":"S Bonvalot","year":"2013","unstructured":"Bonvalot S, Tern\u00e8s N, Fiore M, Bitsakou G, Colombo C, Honor\u00e9 C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096\u2013102.","journal-title":"Ann Surg Oncol"},{"key":"526_CR39","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","volume":"379","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Mahoney MR, Tine BAV, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379:2417\u201328.","journal-title":"N Engl J Med"},{"key":"526_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.06.017","volume":"83","author":"N Penel","year":"2017","unstructured":"Penel N, Cesne AL, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125\u201331.\u00a0","journal-title":"Eur J Cancer"},{"key":"526_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/08880018.2014.956905","volume":"32","author":"N Woltsche","year":"2014","unstructured":"Woltsche N, Gilg MM, Fraissler L, Liegl-Atzwanger B, Beham A, Lackner H, et al. Is wide resection obsolete for desmoid tumors in children and adolescents? Evaluation of histological margins, immunohistochemical markers, and review of literature. Pediatr Hemat Oncol. 2014;32:60\u20139.","journal-title":"Pediatr Hemat Oncol."},{"key":"526_CR42","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ejso.2020.02.028","volume":"46","author":"GD de B\u00e9naz\u00e9","year":"2020","unstructured":"de B\u00e9naz\u00e9 GD, Vigan M, Corradini N, Minard-Colin V, Marie-Cardine A, Verite C, et al. Functional analysis of young patients with desmoid-type fibromatosis: initial surveillance does not jeopardize long term quality of life. Eur J Surg Oncol. 2020;46:1294\u2013300.","journal-title":"Eur J Surg Oncol"},{"key":"526_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijrobp.2008.10.072","volume":"75","author":"S Jabbari","year":"2009","unstructured":"Jabbari S, Andolino D, Weinberg V, Missett BT, Law J, Wara WM, et al. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys. 2009;75:177\u201382.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"526_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijrobp.2007.10.013","volume":"71","author":"BA Guadagnolo","year":"2008","unstructured":"Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71:441\u20137.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"526_CR45","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0360-3016(00)00566-6","volume":"47","author":"TE Merchant","year":"2000","unstructured":"Merchant TE, Nguyen D, Walter AW, Pappo AS, Kun LE, Rao BN. Long-term results with radiation therapy for pediatric desmoid tumors. Int J Radiat Oncol Biol Phys. 2000;47:1267\u201371.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"526_CR46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jvir.2021.05.025","volume":"32","author":"YY Yan","year":"2021","unstructured":"Yan YY, Walsh JP, Munk PL, Mallinson PI, Simmons C, Clarkson PW, et al. A single-center 10-year retrospective analysis of cryoablation for the management of desmoid tumors. J Vasc Interv Radiol. 2021;32:1277\u201387.","journal-title":"J Vasc Interv Radiol"},{"key":"526_CR47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/diagnostics10080556","volume":"10","author":"S Saltiel","year":"2020","unstructured":"Saltiel S, Bize PE, Goetti P, Gallusser N, Cherix S, Denys A, et al. Cryoablation of extra-abdominal desmoid tumors: a single-center experience with literature review. Diagnostics. 2020;10:556.","journal-title":"Diagnostics"},{"key":"526_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00256-009-0807-6","volume":"39","author":"H Ilaslan","year":"2009","unstructured":"Ilaslan H, Schils J, Joyce M, Marks K, Sundaram M. Radiofrequency ablation: another treatment option for local control of desmoid tumors. Skelet Radiol. 2009;39:169.","journal-title":"Skelet Radiol"},{"key":"526_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3348\/kjr.2020.0768","volume":"22","author":"A Mart\u00ednez-Mart\u00ednez","year":"2021","unstructured":"Mart\u00ednez-Mart\u00ednez A, Garc\u00eda-Espinosa J, Ramos-Bossini AJL, Santiago FR. Percutaneous microwave ablation of desmoid fibromatosis. Korean J Radiol. 2021;22:944\u201350.","journal-title":"Korean J Radiol"},{"key":"526_CR50","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s00330-016-4376-5","volume":"27","author":"P Ghanouni","year":"2017","unstructured":"Ghanouni P, Dobrotwir A, Bazzocchi A, Bucknor M, Bitton R, Rosenberg J, et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol. 2017;27:732\u201340.","journal-title":"Eur Radiol"},{"key":"526_CR51","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jvir.2018.04.009","volume":"29","author":"E Elnekave","year":"2018","unstructured":"Elnekave E, Atar E, Amar S, Bruckheimer E, Knizhnik M, Yaniv I, et al. Doxorubicin-eluting intra-arterial therapy for pediatric extra-abdominal desmoid fibromatoses: a promising approach for a perplexing disease. J Vasc Interv Radiol. 2018;29:1376\u201382.","journal-title":"J Vasc Interv Radiol"},{"key":"526_CR52","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2001.19.1.191","volume":"19","author":"LCM Kremer","year":"2001","unstructured":"Kremer LCM, van Dalen EC, Offringa M, Ottenkamp J, Vo\u00fbte PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191\u20136.","journal-title":"J Clin Oncol"},{"key":"526_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1542\/peds.63.1.157","volume":"1","author":"RJ Hutchinson","year":"1979","unstructured":"Hutchinson RJ, Norris DG, Schnaufer L. Chemotherapy: a successful applicationin in abdominal fibromatosis. Pediatrics. 1979;1:157\u20139.","journal-title":"Pediatrics"},{"key":"526_CR54","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1542\/peds.79.3.394","volume":"79","author":"B Raney","year":"1987","unstructured":"Raney B, Evans A, Granowetter L, Schnaufer L, Uri A, Littman P. Nonsurgical management of children with recurrent or unresectable fibromatosis. Pediatrics. 1987;79:394\u20138.","journal-title":"Pediatrics"},{"key":"526_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26943","volume":"65","author":"M Sparber-Sauer","year":"2018","unstructured":"Sparber-Sauer M, Seitz G, Kalle T, Vokuhl C, Leuschner I, Scheer M, et al. Systemic therapy of aggressive fibromatosis in children and adolescents: report of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer. 2018;65: e26943.","journal-title":"Pediatr Blood Cancer"},{"key":"526_CR56","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/annonc\/mdr051","volume":"23","author":"D Garbay","year":"2012","unstructured":"Garbay D, Cesne AL, Penel N, Chevreau C, Marec-Berard P, Blay J-Y, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2012;23:182\u20136.","journal-title":"Ann Oncol"},{"key":"526_CR57","unstructured":"Dalen EC van, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;CD005006."},{"key":"526_CR58","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1016\/j.ejca.2009.08.016","volume":"45","author":"A Constantinidou","year":"2009","unstructured":"Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009;45:2930\u20134.","journal-title":"Eur J Cancer"},{"key":"526_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26375","volume":"64","author":"P Ananth","year":"2017","unstructured":"Ananth P, Werger A, Voss S, Rodriguez-Galindo C, Janeway KA. Liposomal doxorubicin: effective treatment for pediatric desmoid fibromatosis. Pediatric Blood Amp Cancer. 2017;64: e26375.","journal-title":"Pediatric Blood Amp Cancer."},{"key":"526_CR60","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.1998.16.9.3021","volume":"16","author":"SX Skapek","year":"1998","unstructured":"Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhardt MC, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol. 1998;16:3021\u20137.","journal-title":"J Clin Oncol"},{"key":"526_CR61","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.1999.17.3.1086","volume":"17","author":"S Reich","year":"1999","unstructured":"Reich S, Overberg-Schmidt US, B\u00fchrer C, Henze G. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J Clin Oncol. 1999;17:1086\u20131086.","journal-title":"J Clin Oncol"},{"key":"526_CR62","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y","volume":"92","author":"A Azzarelli","year":"2001","unstructured":"Azzarelli A, Gronchi A, Bertulli R, Tess JDT, Baratti D, Pennacchioli E, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92:1259\u201364.","journal-title":"Cancer"},{"key":"526_CR63","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.2006.08.2966","volume":"25","author":"SX Skapek","year":"2007","unstructured":"Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial. J Clin Oncol. 2007;25:501\u20136.","journal-title":"J Clin Oncol"},{"key":"526_CR64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207\u201314.","journal-title":"Cancer"},{"key":"526_CR65","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1002\/cam4.2374","volume":"8","author":"KM Ingley","year":"2019","unstructured":"Ingley KM, Burtenshaw SM, Theobalds NC, White LM, Blackstein ME, Gladdy RA, et al. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI. Cancer Med-us. 2019;8:5047\u201357.","journal-title":"Cancer Med-us."},{"key":"526_CR66","doi-asserted-by":"publisher","first-page":"e2013","DOI":"10.1002\/ONCO.13516","volume":"25","author":"S Gennatas","year":"2020","unstructured":"Gennatas S, Chamberlain F, Smrke A, Stewart J, Hayes A, Roden L, et al. A timely oral option: single-agent vinorelbine in desmoid tumors. Oncol. 2020;25:e2013\u20136.","journal-title":"Oncol"},{"key":"526_CR67","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-20-1847","volume":"26","author":"O Mir","year":"2020","unstructured":"Mir O, Honor\u00e9 C, Chamseddine AN, D\u00f4mont J, Dumont SN, Cavalcanti A, et al. Long-term outcomes of oral vinorelbine in advanced, progressive desmoid fibromatosis and influence of CTNNB1 mutational status. Clin Cancer Res. 2020;26:6277\u201383.","journal-title":"Clin Cancer Res"},{"key":"526_CR68","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1158\/1078-0432.CCR-05-1541","volume":"12","author":"M Johansen","year":"2006","unstructured":"Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the children\u2019s oncology group. Clin Cancer Res. 2006;12:516\u201322.","journal-title":"Clin Cancer Res"},{"key":"526_CR69","doi-asserted-by":"crossref","unstructured":"Hamimed M, Gattacceca F, Andr\u00e9 N, Tresch-Bruneel E, Probst A, Chastagner P, et al. Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low\u2010grade glioma. Br J Clin Pharmacol. 2021;1\u201322.","DOI":"10.1111\/bcp.15131"},{"key":"526_CR70","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","volume":"23","author":"HB Newton","year":"2007","unstructured":"Newton HB. Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus. 2007;23:E11.","journal-title":"Neurosurg Focus"},{"key":"526_CR71","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/pbc.22623","volume":"55","author":"C Meazza","year":"2010","unstructured":"Meazza C, Casanova M, Trecate G, Ferrari A. Objective response to hydroxyurea in a patient with heavily pre-treated aggressive fibromatosis. Pediatr Blood Cancer. 2010;55:588\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"526_CR72","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1097\/MPH.0b013e3182678d25","volume":"35","author":"G Bisogno","year":"2013","unstructured":"Bisogno G, Tagarelli A, Stramare R, Beltrame V, Carli M. Hydroxyurea treatment can avoid the need for aggressive surgery in pediatric fibromatosis. J Pediatr Hematology Sol Oncol. 2013;35:e171\u20133.","journal-title":"J Pediatr Hematology Sol Oncol."},{"key":"526_CR73","unstructured":"Womer R. Successful treatment of fibromatosis with hydroxurea: analysis of 20 pediatric cases. Annual Meeting of the Connective Tissue Oncology Society, London; 2008."},{"key":"526_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27472","volume":"66","author":"A Ferrari","year":"2019","unstructured":"Ferrari A, Orbach D, Affinita MC, Chiaravalli S, Corradini N, Meazza C, et al. Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: a new option in the armamentarium of systemic therapies. Pediatr Blood Cancer. 2019;66: e27472.","journal-title":"Pediatr Blood Cancer"},{"key":"526_CR75","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0092-8674(00)81983-2","volume":"87","author":"SM Prescott","year":"1996","unstructured":"Prescott SM, White RL. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell. 1996;87:783\u20136.","journal-title":"Cell"},{"key":"526_CR76","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","volume":"342","author":"G Steinbach","year":"2000","unstructured":"Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946\u201352.","journal-title":"N Engl J Med"},{"key":"526_CR77","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0092-8674(00)81664-5","volume":"99","author":"T-C He","year":"1999","unstructured":"He T-C, Chan TA, Vogelstein B, Kinzler KW. PPAR\u03b4 is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335\u201345.","journal-title":"Cell"},{"key":"526_CR78","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S0959-8049(09)70092-9","volume":"45","author":"C Colombo","year":"2009","unstructured":"Colombo C, Gronchi A. Desmoid-type fibromatosis: what works best? Eur J Cancer. 2009;45:466\u20137.","journal-title":"Eur J Cancer"},{"key":"526_CR79","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<334::AID-CNCR22>3.0.CO;2-U","volume":"80","author":"H Lackner","year":"1997","unstructured":"Lackner H, Urban C, Kerbl R, Schwinger W, Beham A. Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer. 1997;80:334\u201340.","journal-title":"Cancer."},{"key":"526_CR80","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/pbc.24457","volume":"60","author":"SX Skapek","year":"2013","unstructured":"Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children\u2019s Oncology Group (COG) Phase II Study. Pediatr Blood Cancer. 2013;60:1108\u201312.","journal-title":"Pediatr Blood Cancer"},{"key":"526_CR81","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41416-021-01320-1","volume":"124","author":"M Sparber-Sauer","year":"2021","unstructured":"Sparber-Sauer M, Orbach D, Navid F, Hettmer S, Skapek S, Corradini N, et al. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. Br J Cancer. 2021;124:1637\u201346.","journal-title":"Br J Cancer"},{"key":"526_CR82","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","volume":"21","author":"AR Weiss","year":"2020","unstructured":"Weiss AR, Chen Y-L, Scharschmidt TJ, Chi Y-Y, Tian J, Black JO, et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21:1110\u201322.","journal-title":"Lancet Oncol"},{"key":"526_CR83","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1002\/cncr.11029","volume":"95","author":"J Mace","year":"2002","unstructured":"Mace J, Biermann JS, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002;95:2373\u20139.","journal-title":"Cancer"},{"key":"526_CR84","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2005.04.0717","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006;24:1195\u2013203.","journal-title":"J Clin Oncol"},{"key":"526_CR85","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdq341","volume":"22","author":"N Penel","year":"2011","unstructured":"Penel N, Cesne AL, Bui BN, Perol D, Brain EG, Ray-Coquard I, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC\/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22:452\u20137.","journal-title":"Ann Oncol"},{"key":"526_CR86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2017.02.001","volume":"76","author":"B Kasper","year":"2017","unstructured":"Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017;76:60\u20137.","journal-title":"Eur J Cancer"},{"key":"526_CR87","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1158\/1078-0432.CCR-11-3284","volume":"18","author":"BC Widemann","year":"2012","unstructured":"Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a children\u2019s oncology group phase I Consortium Report. Clin Cancer Res. 2012;18:6011\u201322.","journal-title":"Clin Cancer Res"},{"key":"526_CR88","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/pbc.25548","volume":"62","author":"A Kim","year":"2015","unstructured":"Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weigel B, et al. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2015;62:1562\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"526_CR89","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/TCRM.S84792","volume":"12","author":"LD Cranmer","year":"2016","unstructured":"Cranmer LD, Loggers ET, Pollack SM. Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag. 2016;12:941\u201355.","journal-title":"Ther Clin Risk Manag"},{"key":"526_CR90","first-page":"53","volume":"4","author":"DT Nguyen","year":"2013","unstructured":"Nguyen DT, Shayahi S. Pazopanib: approval for soft-tissue sarcoma. J Adv Pract Oncol. 2013;4:53\u20137.","journal-title":"J Adv Pract Oncol"},{"key":"526_CR91","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","volume":"20","author":"M Toulmonde","year":"2019","unstructured":"Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, et al. Pazopanib or methotrexate\u2013vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20:1263\u201372.","journal-title":"Lancet Oncol"},{"key":"526_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26968","volume":"65","author":"L Agresta","year":"2018","unstructured":"Agresta L, Kim H, Turpin BK, Nagarajan R, Plemmons A, Szabo S, et al. Pazopanib therapy for desmoid tumors in adolescent and young adult patients. Pediatr Blood Cancer. 2018;65: e26968.","journal-title":"Pediatr Blood Cancer"},{"key":"526_CR93","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","volume":"31","author":"JLG Bender","year":"2013","unstructured":"Bender JLG, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children\u2019s oncology group phase I consortium report. J Clin Oncol. 2013;31:3034\u201343.","journal-title":"J Clin Oncol"},{"key":"526_CR94","doi-asserted-by":"crossref","unstructured":"Li X, von Boehmer H. Notch signaling in T-cell development and T-ALL. Isrn Hematol. 2011;2011:1\u20139.","DOI":"10.5402\/2011\/921706"},{"key":"526_CR95","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/cells9061503","volume":"9","author":"G Moore","year":"2020","unstructured":"Moore G, Annett S, McClements L, Robson T. Top notch targeting strategies in cancer: a detailed overview of recent insights and current perspectives. Cells. 2020;9:1503.","journal-title":"Cells"},{"key":"526_CR96","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pharmthera.2013.09.005","volume":"141","author":"N Takebe","year":"2014","unstructured":"Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141:140\u20139.","journal-title":"Pharmacol Ther."},{"key":"526_CR97","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-09-2823","volume":"16","author":"A Pannuti","year":"2010","unstructured":"Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting notch to target cancer stem cells. Clin Cancer Res. 2010;16:3141\u201352.","journal-title":"Clin Cancer Res"},{"key":"526_CR98","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","volume":"67","author":"I-M Shih","year":"2007","unstructured":"Shih I-M, Wang T-L. Notch signaling, \u03b3-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67:1879\u201382.","journal-title":"Cancer Res"},{"key":"526_CR99","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","volume":"21","author":"WA Messersmith","year":"2015","unstructured":"Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral \u03b3-secretase inhibitor PF-03084014. Clin Cancer Res. 2015;21:60\u20137.","journal-title":"Clin Cancer Res"},{"key":"526_CR100","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1245\/s10434-017-6082-1","volume":"25","author":"VM Villalobos","year":"2018","unstructured":"Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, et al. Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral gamma secretase inhibitor. Ann Surg Oncol. 2018;25:768\u201375.","journal-title":"Ann Surg Oncol"},{"key":"526_CR101","doi-asserted-by":"crossref","unstructured":"Kummar S, Coyne GO, Do KT, Turkbey B, Meltzer PS, Polley E, et al. Clinical activity of the \u03b3-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol. 2017;35:1561\u201369.","DOI":"10.1200\/JCO.2016.71.1994"},{"key":"526_CR102","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.1021\/acs.jmedchem.5b00460","volume":"58","author":"R Soldi","year":"2015","unstructured":"Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, et al. Design, synthesis, and biological evaluation of a series of anthracene-9,10-dione dioxime \u03b2-catenin pathway inhibitors. J Med Chem. 2015;58:5854\u201362.","journal-title":"J Med Chem"},{"key":"526_CR103","doi-asserted-by":"publisher","first-page":"13507","DOI":"10.1074\/jbc.M109.049411","volume":"285","author":"YN Dimitrova","year":"2010","unstructured":"Dimitrova YN, Li J, Lee Y-T, Rios-Esteves J, Friedman DB, Choi H-J, et al. Direct ubiquitination of \u03b2-catenin by Siah-1 and regulation by the exchange factor TBL1*. J Biol Chem. 2010;285:13507\u201316.","journal-title":"J Biol Chem"},{"key":"526_CR104","doi-asserted-by":"publisher","first-page":"11523","DOI":"10.1200\/JCO.2022.40.16_suppl.11523","volume":"40","author":"LD Cranmer","year":"2022","unstructured":"Cranmer LD, Razak ARA, Ratan R, Choy E, George S, Liebner DA, et al. Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor. J Clin Oncol. 2022;40:11523.","journal-title":"J Clin Oncol"},{"key":"526_CR105","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","volume":"127","author":"B Alman","year":"2020","unstructured":"Group TDTW, Alman B, Attia S, Baumgarten C, Benson C, Blay J-Y, et al. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96\u2013107.","journal-title":"Eur J Cancer"},{"key":"526_CR106","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2350\/11-07-1064-OA.1","volume":"15","author":"W-L Wang","year":"2012","unstructured":"Wang W-L, Nero C, Pappo A, Lev D, Lazar AJ, L\u00f3pez-Terrada D. CTNNB1 Genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm. Pediatr Devel Pathol. 2012;15:361\u20137.","journal-title":"Pediatr Devel Pathol."},{"key":"526_CR107","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer."},{"key":"526_CR108","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.1002\/cam4.3973","volume":"10","author":"E Zanchetta","year":"2021","unstructured":"Zanchetta E, Ciniselli CM, Bardelli A, Colombo C, Stacchiotti S, Baldi GG, et al. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. Cancer Med-US. 2021;10:4356\u201365.","journal-title":"Cancer Med-US."},{"key":"526_CR109","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00256-016-2439-y","volume":"45","author":"PJ Sheth","year":"2016","unstructured":"Sheth PJ, del Moral S, Wilky BA, Trent JC, Cohen J, Rosenberg AE, et al. Desmoid fibromatosis: MRI features of response to systemic therapy. Skelet Radiol. 2016;45:1365\u201373.","journal-title":"Skelet Radiol"},{"key":"526_CR110","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2021210016","volume":"3","author":"TK Subhawong","year":"2021","unstructured":"Subhawong TK, Feister K, Sweet K, Alperin N, Kwon D, Rosenberg A, et al. MRI volumetrics and image texture analysis in assessing systemic treatment response in extra-abdominal desmoid fibromatosis. Radiol Imaging Cancer. 2021;3: e210016.","journal-title":"Radiol Imaging Cancer."},{"key":"526_CR111","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1148\/radiol.2512081403","volume":"251","author":"S Stacchiotti","year":"2009","unstructured":"Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, et al. High-grade soft-tissue sarcomas: tumor response assessment\u2014pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi Criteria. Radiology. 2009;251:447\u201356.","journal-title":"Radiology"},{"key":"526_CR112","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2214\/AJR.07.2334","volume":"189","author":"MB McCarville","year":"2007","unstructured":"McCarville MB, Hoffer FA, Adelman CS, Khoury JD, Li C, Skapek SX. MRI and biologic behavior of desmoid tumors in children. Am J Roentgenol. 2007;189:633\u201340.","journal-title":"Am J Roentgenol"},{"key":"526_CR113","doi-asserted-by":"crossref","unstructured":"Cassidy MR, Lefkowitz RA, Long N, Qin L-X, Kirane A, Sbaity E, et al. Association of MRI T2 signal intensity with desmoid tumor progression during active observation. Ann Surg. 2020;4:748\u201355.","DOI":"10.1097\/SLA.0000000000003073"},{"key":"526_CR114","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cncr.32555","volume":"126","author":"MM Gounder","year":"2020","unstructured":"Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer. 2020;126:531\u20139.","journal-title":"Cancer"},{"key":"526_CR115","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1002\/cncr.28271","volume":"119","author":"C Colombo","year":"2013","unstructured":"Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Cesne A, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. Cancer. 2013;119:3696\u2013702.","journal-title":"Cancer"},{"key":"526_CR116","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1245\/s10434-014-4156-x","volume":"22","author":"DLM van Broekhoven","year":"2015","unstructured":"van Broekhoven DLM, Verhoef C, Gr\u00fcnhagen DJ, van Gorp JMHH, den Bakker MA, Hinrichs JWJ, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22:1464\u201370.","journal-title":"Ann Surg Oncol"},{"key":"526_CR117","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2350\/10-07-0866-OA.1","volume":"15","author":"N Bo","year":"2012","unstructured":"Bo N, Wang D, Wu B, Chen L, Ma R. Analysis of \u03b2-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis. Pediatr Devel Pathol. 2012;15:173\u20138.","journal-title":"Pediatr Devel Pathol."},{"key":"526_CR118","doi-asserted-by":"publisher","first-page":"18296","DOI":"10.18632\/oncotarget.24817","volume":"9","author":"N Macagno","year":"2018","unstructured":"Macagno N, Fina F, Penel N, Bouvier C, Nanni I, Duffaud F, et al. Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR. Oncotarget. 2018;9:18296\u2013308.","journal-title":"Oncotarget"},{"key":"526_CR119","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2020.12.001","volume":"145","author":"S Kohsaka","year":"2021","unstructured":"Kohsaka S, Hirata M, Ikegami M, Ueno T, Kojima S, Sakai T, et al. Comprehensive molecular and clinicopathological profiling of desmoid tumours. Eur J Cancer. 2021;145:109\u201320.","journal-title":"Eur J Cancer"},{"key":"526_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250072","volume":"16","author":"T Yamano","year":"2021","unstructured":"Yamano T, Kubo S, Sonoda E, Kominato T, Kimura K, Yasuhara M, et al. Assessment of circulating microRNA specific for patients with familial adenomatous polyposis. PLoS ONE. 2021;16: e0250072.","journal-title":"PLoS ONE"},{"key":"526_CR121","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.18632\/oncotarget.27622","volume":"11","author":"MT Rotelli","year":"2020","unstructured":"Rotelli MT, Refolo MG, Lippolis C, Cavallini A, Picciariello A, Piscitelli D, et al. The role of miRNA-133b and its target gene SIRT1 in FAP-derived desmoid tumor. Oncotarget. 2020;11:2484\u201392.","journal-title":"Oncotarget"},{"key":"526_CR122","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/cas.12640","volume":"106","author":"A Dufresne","year":"2015","unstructured":"Dufresne A, Paturel M, Alberti L, Philippon H, Duc A, Decouvelaere A-V, et al. Prediction of desmoid tumor progression using miRNA expression profiling. Cancer Sci. 2015;106:650\u20135.","journal-title":"Cancer Sci"},{"key":"526_CR123","unstructured":"Alman B. A Genetically-targeted mouse model of desmoid tumors [Internet]. https:\/\/dtrf.org\/desmoid-mouse-models\/."},{"key":"526_CR124","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1001\/jamaoncol.2018.6449","volume":"5","author":"A Gronchi","year":"2019","unstructured":"Gronchi A, Jones RL. Treatment of desmoid tumors in 2019. Jama Oncol. 2019;5:567\u20138.","journal-title":"Jama Oncol"},{"key":"526_CR125","unstructured":"Weiss A. DTRF-sponsored virtual tumor board [Internet]. https:\/\/dtrf.org\/tumorboard\/."},{"key":"526_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2036361320984532","volume":"12","author":"AR Weiss","year":"2020","unstructured":"Weiss AR, Portnoy M, Whiting J, Dileo P. Successful implementation of an international desmoid tumor virtual tumor board: a novel platform for the management of rare tumors. Rare Tumors. 2020;12:1\u20139.","journal-title":"Rare Tumors."},{"key":"526_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2036361319880978","volume":"11","author":"KA Mercier","year":"2019","unstructured":"Mercier KA, Walsh DM. The initiation, design, and establishment of the Desmoid Tumor Research Foundation Patient Registry and Natural History Study. Rare Tumors. 2019;11:1\u20137.","journal-title":"Rare Tumors."},{"key":"526_CR128","doi-asserted-by":"crossref","unstructured":"Hawkins DS, Bisogno G, Koscielniak E. Introducing INSTRuCT: an international effort to promote cooperation and data sharing. Pediatr Blood Cancer. 2020;e28701","DOI":"10.22541\/au.159969688.84945691"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00526-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T03:12:46Z","timestamp":1700881966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00526-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":128,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00526-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"7 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DPD and FN declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. ARW receives funding for travel and lodging associated with his role on the medical advisory board of SpringWorks Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to the conception or design of the work, revised it critically for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}